The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Britain says it expects its vaccine contracts to be met

Fri, 29th Jan 2021 08:23

* UK refuses to publish Astra supply details

* Scotland says it will publish vaccine supply data

* EU warns drug companies over supply delays
(Adds UK PM Johnson's spokesman, Scottish health minister)

By Sarah Young and William James

LONDON, Jan 29 (Reuters) - Britain is confident it will
receive sufficient COVID-19 vaccine doses to keep its programme
on track despite a dispute between the European Union and
drugmaker AstraZeneca, Prime Minister Boris Johnson's spokesman
said on Friday.

EU Commission Head Ursula von der Leyen has demanded that
Astrazeneca deliver contracted vaccine supplies from Britain to
EU states, and has dimissed the notion that the United Kingdom
should have first rights to doses produced there.

The EU has warned drug companies that it would use all legal
means or even block exports unless they agreed to deliver shots
as promised.

The bloc published its contract with AstraZeneca on Friday,
which said the Anglo-Swedish drugmaker should use facilities in
Britain as well as continental Europe in its best efforts to
manufacture its vaccines for the EU.

Prime Minister Boris Johnson's spokesman said on Friday the
government would not discuss contractual matters. But he said
the government expected contracts to be "facilitated" and he was
confident of its supply.

"AstraZeneca has clearly stated they will be able to provide
2 million vaccine doses a week and we've said we will get that
to people as quickly as possible," he said.

While Britain is running ahead of its European peers on
vaccinations, with almost 7.5 million receiving their first dose
so far, the British COVID-19 death toll has surpassed 100,000,
and is the highest in Europe.

A third national lockdown in England is expected to run
until at least March as ministers try to bring a more contagious
variant of the virus under control. Scotland, Wales and Northern
Ireland, whose governments decide on their own measures, are
also living under tight restrictions.

AHEAD ON MANUFACTURING

The swiftest mass vaccination drive in history is stoking
tensions across the world as big powers buy up doses in bulk and
poorer nations try to navigate a financial and diplomatic
minefield to collect whatever supplies are left.

The United Kingdom has secured 367 million doses of the
seven most promising vaccines, including 100 million doses of
the AstraZeneca vaccine which was developed by Oxford
University.

Among those procured by Britain include a vaccine developed
by Novavax, which on Thursday said it proved 89%
effective in a UK trial, and Johnson & Johnson, which on Friday
said its shot was between 72% to 66% effective.

Kate Bingham, the former head of Britain's vaccine
taskforce, said the country had been able to secure supplies by
supporting pharmaceutical companies, setting up clinical trials
quickly and helping firms procure equipment to increase
manufacturing.

She declined to comment on the detail of the contract with
AstraZeneca but said the United Kingdom had benefited from early
work to be ready to make vaccines.

"That is ultimately the difference as to why we're so far
ahead on manufacturing," Bingham said, adding that she did not
expect the EU to block vaccine exports to the United Kingdom.

NO LONGER TENABLE

Scotland will publish COVID-19 detailed vaccine supply data
next week even though the British government has refused to do
so.

British prisons minister Lucy Frazer said the government
could not publish supply details for national security reasons,
which she declined to specify.

Scotland's health minister Jeane Freeman said that citing
national security was "not credible" because the British
government had repeatedly briefed statistics to reporters
showing how much vaccine Scotland had been allocated.

"We've held off publication in the past at their request.
But that's no longer tenable," she said at a news conference.

"The public have a right to clarity and we will give them
that. We're not talking about future supplies, we're talking
about known supplies."
(Reporting by Sarah Young, Alistair Smout and William James;
editing by Angus MacSwan)

More News
8 Feb 2024 12:08

LONDON MARKET MIDDAY: DS Smith surges on takeover approach from Mondi

(Alliance News) - Stock prices in London were mixed at midday Thursday, as markets struggled to find direction amid a mixed wave of corporate updates and earnings.

Read more
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.